Most Prescriptions for Opioid Addiction Medication Buprenorphine Are Written by a Small Number of Providers
Jun 1, 2021
Published in: JAMA, Volume 325, Number 21, pages 2206-2208 (2021). doi: 10.1001/jama.2021.4469
Posted on RAND.org on June 10, 2021
|PDF file||0.1 MB||
Use Adobe Acrobat Reader version 10 or higher for the best experience.
|zip file||3.7 MB||
The file(s) provided above are ZIP-formatted archives, which most modern systems can natively unpack. If your computer does not unpack the archive when you double-click it, you may need to use a separate decompression program such as UnZip.
In the US, buprenorphine to treat opioid use disorder can be prescribed only by qualified clinicians. Policy initiatives and advocacy, such as efforts to remove the training requirements required for buprenorphine prescribing, have commonly focused on enlarging the pool of clinicians allowed to prescribe buprenorphine; current legislation under consideration in the US Congress would eliminate these requirements. However, many trained buprenorphine prescribers are not actively prescribing or are treating few patients, and the overall concentration of patient care among prescribers is not well characterized. We quantified the total amount of buprenorphine care delivered by active prescribers and to what extent that varies across specialties.
This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.